ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that the company will present at the Raymond James Institutional Investors Conference in Orlando, Florida on Monday, March 2 at 1:40 p.m. Eastern Time. A live audio webcast of the session will be available at https://investors.guardianpharmacy.com. A replay of the webcast will be accessible shortly after the event and will remain available for 90 days. About Guardian Pharmacy Services Guardian Pharmacy Servi. ...

Company Overview - Guardian Pharmacy Services was founded in 2004 by Fred Burke, David Morris, and Kendall Forbes, who have extensive experience in building and scaling healthcare services businesses, including a previous nuclear pharmacy platform that was sold [4]. Leadership Team - The leadership team includes Fred Burke as President and CEO, David Morris as Chief Financial Officer, and Ashley Stockton as Senior Director of Investor Relations [2][4]. Presentation Context - The presentation is part of a moderated Q&A session, indicating an interactive approach to discussing the company's future and financial outlook [1].

Guardian Pharmacy Services FY Conference Summary Company Overview - **Company**: Guardian Pharmacy Services (NYSE: GRDN) - **Founded**: 2004 - **Focus**: Long-term care pharmacy services, primarily for assisted living facilities (ALFs) - **Market Position**: Leader in the ALF market, which is the fastest-growing segment of the long-term care industry, supported by strong demographic trends [3][4] Industry Insights - **Market Size**: Approximately $7 billion in drug spend with 1 million residents in ALFs [8] - **Competitive Landscape**: Highly fragmented with many independent pharmacies as key competitors; Guardian holds a 13% market share nationally [9][10] - **Challenges**: ALFs lack dedicated medical staff for medication management, leading to complex drug regimens for residents [3][4] Business Model and Strategy - **Core Pillars**: 1. Multi-pronged growth strategy leveraging organic growth and M&A [4] 2. National scale enhancing profitability through data analytics [5] 3. Reinvestment in services and technology for competitive advantages [5] 4. Strong financial performance with a healthy balance sheet and virtually zero debt [5] 5. Experienced management team with significant ownership aligning with shareholders [6] Growth Strategy - **Organic Growth**: Focus on onboarding new ALFs and increasing adoption rates within existing facilities [11] - **M&A Strategy**: Targeting independent pharmacy operators with revenues of $10-30 million, aiming for collaborative growth [12][14] - **Integration Focus**: Enhancing operations through reimbursement management, margin tools, and purchasing platforms post-acquisition [13] Financial Performance - **CAGR**: Approximately 16% from 2012 to 2025 [18] - **Adjusted EBITDA**: Expected growth from $105 million in 2025 to $116.5 million in 2026, with margins projected to exceed 8% [22] - **Cash Flow**: Average cash conversion rate of approximately 60% after CapEx and tax payments [19] Regulatory Impact - **Inflation Reduction Act (IRA)**: Expected to impact margins by requiring sales of branded drugs at the manufacturer's fair price, necessitating coordination with payors to offset losses [20][21] Future Outlook - **2026 Guidance**: Revenue projected between $1.4 billion and $1.42 billion, with adjusted EBITDA between $115 million and $118 million [22] - **Market Opportunities**: Potential for significant growth given the 87% market share still available; focus on geographic expansion through M&A and greenfield startups [36][38] Competitive Advantages - **Data Analytics**: Proprietary platforms (Guardian Compass and Guardian Shield) used to optimize pharmacy operations and demonstrate value to partners [16][17] - **Cost Savings**: Over $41 million saved for residents through proper formulary management [17] Key Takeaways - **Employee Engagement**: Going public has enhanced employee motivation and belief in the company's growth potential [24][25] - **Underappreciated Aspects**: The importance of data analytics and operational support in improving clinical outcomes and profitability is still being communicated to investors [39][40] This summary encapsulates the key points from the Guardian Pharmacy Services FY Conference, highlighting the company's strategic positioning, growth opportunities, and financial outlook within the long-term care pharmacy industry.

Business Overview - Guardian Pharmacy Services focuses on the Assisted Living Facilities (ALF) market, which is estimated to be around $7 billion[14] - The company has a 13% market share nationwide in the ALF & Memory Care market[22, 23] - Guardian serves approximately 140,000+ ALF residents and 204,000+ total residents[22] - The company dispenses approximately 28 million prescriptions annually[22] Financial Performance - The company's revenue for 2025 is projected to be $1.44 billion[60, 84] - Adjusted EBITDA for 2025 is projected to be $104-$106 million[81] - The company anticipates an Adjusted EBITDA margin of over 8% in 2026[81] - The company's cash conversion rate is approximately 60% year-to-date as of September 30, 2025[69, 70] Growth Strategy - The company is expanding into adjacent and new underserved markets through greenfield startups[37] - The company is targeting acquisitions with revenues between $10 million and $30 million, serving approximately 2,000 to 3,500 residents[42] - The company is implementing initiatives to mitigate the impact of the Inflation Reduction Act (IRA)[76]

Market Overview - Guardian operates in the Assisted Living Facilities (ALF) market, which is valued at approximately $7 billion, focusing on medication management for residents who typically require 12-14 prescriptions daily[7]. - The ALF market is characterized by a highly fragmented landscape with over 1,200 independent pharmacies, presenting significant opportunities for market share expansion[7][10]. Business Model and Strategy - Guardian's business model emphasizes local service combined with centralized support, resulting in improved accuracy and adherence in medication management[5][9]. - The company has a multi-pronged growth strategy that includes organic growth, expansion into new facilities, and disciplined mergers and acquisitions[5][12]. - Guardian's management team is co-founder-led, with a strong focus on capital allocation and operational excellence, contributing to consistent growth and profitability[5]. - The company has established a defensible competitive moat through its service-led, tech-enabled model, which enhances medication care coordination[5]. Financial Performance - Guardian's financial performance is supported by durable margins and a healthy balance sheet, indicating resilience in its business operations[5]. - Projected revenue for 2025 is estimated to be between $1.40 billion and $1.42 billion, with adjusted EBITDA guidance of $104 million to $106 million for 2026[30]. - The company has demonstrated a consistent track record of growth, with an estimated revenue CAGR of approximately 16% from 2012 to 2025[23]. - The company reported a cash conversion rate of approximately 60% for the year-to-date as of September 30, 2025, indicating strong cash flow management[26]. - The adjusted EBITDA margin is projected to exceed 8% for 2025, reflecting ongoing profitability improvements[30]. Growth Initiatives - The company aims to increase its market presence by adding new facilities and launching greenfield startups to drive organic growth[13]. - The company is expanding into new underserved markets with 20 greenfield start-ups planned from 2022 to 2025, including locations in Florida, Ohio, and Oklahoma[14]. - The target pool for M&A acquisitions includes approximately 100 potential targets, with typical target sizes ranging from $10 million to $30 million in revenue and 2,000 to 3,500 residents[15]. - The company aims for high single-digit organic growth at targeted operating margins in regions like Eastern Michigan and Northern Virginia[17]. Operational Metrics - As of September 30, 2025, Guardian processed approximately 28 million prescriptions, showcasing its scale and operational efficiency[9]. - As of September 30, 2025, the resident count is projected to reach 204,000, with prescription growth expected to increase to 28 million[24]. Regulatory Impact - The Inflation Reduction Act (IRA) will impact key branded drugs, with negotiated lower prices expected to affect revenue streams starting in 2026[28]. - The company is implementing efficiency improvements and purchasing optimization initiatives to mitigate the impact of the IRA on its business[29].

Company Participation - Guardian Pharmacy Services, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA [1] - The company's leadership team will host investor meetings on January 14 and present at 4:30 p.m. PT on the same day [1] - A live audio webcast of the session will be available, with a replay accessible for 30 days after the event [1] Company Overview - Guardian Pharmacy Services is one of the leading long-term care pharmacy services companies in the nation [2] - The company partners with long-term care facilities to deliver medications and technology-enabled services aimed at enhancing care and improving adherence to drug regimens [2] - Guardian operates a network of over 53 pharmacies nationwide, serving close to 204,000 residents as of September 30, 2025 [2]

Group 1: Market Movements - Several healthcare and biotech companies experienced notable gains in after-hours trading, driven by clinical updates, recent announcements, and technical rebounds [1] - Kymera Therapeutics Inc. (KYMR) saw a 9.58% increase to $73.00 after hours, following a modest 0.59% rise during the regular session [2] - Ocular Therapeutix Inc. (OCUL) advanced 11.29% to $14.00 after hours, with a 1.21% increase during the day [3] - Guardian Pharmacy Services Inc. (GRDN) shares rose 2.62% to $30.54 in after-hours trading, extending its earlier 1.50% gain [4] - Predictive Oncology Inc. (POAI) jumped 13.62% to $4.84 after hours, recovering from a 22% decline during the regular session [5] - Acumen Pharmaceuticals Inc. (ABOS) edged up 3.23% to $1.92 after hours, following a 6.06% drop during the day [6] - EUDA Health Holdings Ltd. (EUDA) rose 7.72% to $2.93 after hours, recovering from a 6.85% decline earlier [7] - Butterfly Network Inc. (BFLY) gained 4.90% to $3.21 after hours, after finishing the regular session flat [8] Group 2: Company-Specific Updates - Kymera Therapeutics is set to announce results from the BroADen Phase 1b clinical trial of KT-621 for atopic dermatitis on December 8, which has fueled after-hours momentum [2] - Ocular Therapeutix recently announced progress in its HELIOS-3 Phase 3 program for AXPAXLI in diabetic retinopathy, with the first patient randomized on November 24 [3] - Predictive Oncology regained compliance with Nasdaq's minimum stockholders' equity requirement, which has renewed investor confidence [5] - Acumen Pharmaceuticals presented new research at the CTAD conference, highlighting advancements in Alzheimer's treatment [6] - EUDA Health announced a securities purchase agreement for a convertible warrant valued at $100,000, providing financing flexibility for growth initiatives [7]

Guardian Pharmacy Services (NYSE:GRDN) FY Conference Summary Company Overview - Guardian Pharmacy Services is a leading long-term care pharmacy provider with over 50 pharmacy operations nationally, primarily focused on assisted living and memory care markets [3][4] - The company holds approximately 13% market share in the assisted living end market and aims to expand to 20-30% over time [3][4] Core Business Model - The business model is centered around providing specialized pharmacy services tailored to the needs of frail and elderly residents in assisted living facilities [6][10] - Guardian's operations leverage scale through purchasing, reimbursement, analytics tools, and strong sales relationships with national accounts [6][10] Market Focus - The assisted living market was chosen due to its significant growth over the past 20 years, with a total addressable market (TAM) of approximately one million residents [10] - The average resident is now older (85+) and takes an average of 14 prescriptions, indicating a shift in the acuity level of residents [10][32] Competitive Landscape - Guardian competes with independent operators who lack the scale and resources to provide the same level of service and analytics [12][58] - The company believes there is ample room for multiple competitors in the assisted living market, despite the presence of larger peers [56][58] Growth Strategy - Organic growth is driven by increasing market share in existing markets and expanding into contiguous markets [15][16] - The company tracks market share using NICMAP data and aims for 50% or more in mature markets [15] - Recent acquisitions in the Pacific Northwest were driven by demand from larger national and regional accounts [22][24] Resident Adoption and Service Efficiency - The current resident adoption rate of Guardian's services is around 89%, with efforts to increase this in new facilities [28] - The company utilizes a tech-enabled platform to ensure safe medication administration, significantly reducing errors [67][70] Financial Outlook - The Inflation Reduction Act (IRA) is expected to impact revenue but not EBITDA, with the company confident in offsetting headwinds through operational efficiencies [38][49] - The company has increased guidance based on favorable organic growth trends and successful flu vaccine clinics [50][52] Adjacent Market Opportunities - Guardian is exploring opportunities in adjacent markets such as PACE and hospice, with ongoing efforts to improve service delivery in these areas [54][55] Conclusion - Guardian Pharmacy Services is well-positioned in the long-term care pharmacy market, with a clear strategy for growth through market share expansion, operational efficiencies, and a focus on specialized services for assisted living facilities [4][10][54]

Core Insights - Guardian Pharmacy Services Inc. reported better-than-expected earnings, leading to a significant stock surge and increased market attention [2][6] - The company operates in the long-term care pharmacy services sector, focusing on technology-driven solutions to improve medication management and health outcomes [3][4] - Guardian's Q3 results showed a 20% year-over-year revenue increase, with revenue reaching $377 million, surpassing analyst estimates [6] Company Overview - Guardian Pharmacy Services specializes in supporting residents of long-term care facilities across the U.S., providing pharmacy management solutions [3] - The company aims to promote health and wellness for older adults and those with complex care needs while reducing operational burdens for caregivers [4] - As of November 2025, Guardian operates over 53 pharmacies serving more than 204,000 residents in 38 states [5] Financial Performance - In Q3, Guardian's revenue increased by 20% year-over-year, driven by a 13% rise in total residents served [6] - The company reported earnings per share (EPS) of 25 cents, exceeding consensus estimates by one cent [6] - Following the strong quarterly performance, Guardian raised its full-year guidance, indicating growing demand and operational strength [5]

Core Insights - Guardian Pharmacy Services reported a strong quarterly earnings performance, leading to a significant increase in its stock price, outperforming the S&P 500 index [1][5] Financial Performance - The company achieved a 20% year-over-year revenue increase, totaling over $377 million, driven by a 13% rise in total residents served, reaching 204,000 [2] - Guardian's net income, not according to GAAP, was $15.7 million, a notable improvement from the previous year's breakeven result [3] - The average analyst estimate for Guardian's third-quarter revenue was $354 million, indicating a solid performance above expectations [4] Management Outlook - CEO Fred Burke expressed confidence in the company's business model, highlighting the combination of local expertise with national resources [5] - The company raised its full-year 2025 revenue guidance to a range of $1.43 billion to $1.45 billion, up from the previous range of $1.39 billion to $1.41 billion [6][7] - Adjusted EBITDA guidance was also increased to $104 million to $106 million, compared to the prior range of $100 million to $102 million [7]